THALIDOMIDE ADMINISTRATION INHIBITS THE CLINICAL EVOLUTION OF THE EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE) IN LEWIS RATS: PRELIMINAR RESULTS

Autores

  • José Otávio do Amaral Corrêa
  • Ivo Martins Malta
  • Helvécio Cardoso Corrêa Póvoa
  • Beatriz Julião Vieira Aarestrup
  • Fernando Monteiro Aarestrup

Resumo

Multiple sclerosis (MS) is a chronic neurodegenerative inflammatory disease of the central nervous system. Several immunomodulatory agents have been used to prevent MS acute exacerbations. Tumor Necrosis factor alpha (TNF-?) and interferon gamma (IFN-?) are two major inflammatory mediators. Recently, we investigated in our laboratory the therapeutic value of thalidomide, a recognized TNF-? inhibitor, for the treatment of MS using the classical Lewis rat model of experimental autoimmune encephalomyelitis ( EAE). The experimental study revealed that thalidomide reduces the incidence of EAE development in 90% of the cases. Hence we hypothesized that thalidomide may be an important therapeutical tool for prevention of acute exacerbations of the MS.

Downloads

Não há dados estatísticos.

Downloads

Publicado

2010-06-21